DRTS — Alpha Tau Medical Cashflow Statement
0.000.00%
- $185.80m
- $131.77m
- 35
- 20
- 60
- 31
Annual cashflow statement for Alpha Tau Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -8.88 | -27.3 | -33.8 | -29.2 | -31.8 |
Depreciation | |||||
Non-Cash Items | 0.646 | 14.1 | 9.21 | 7.63 | 9.7 |
Other Non-Cash Items | |||||
Changes in Working Capital | 0.899 | 0.585 | -0.307 | 2.49 | 1.17 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -7.25 | -11.8 | -23.9 | -18 | -19.8 |
Capital Expenditures | -3.77 | -2.93 | -0.904 | -6.4 | -2.24 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -4.05 | 22.2 | -89 | 25.1 | 23 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -7.82 | 19.3 | -89.9 | 18.7 | 20.8 |
Financing Cash Flow Items | 0 | 0 | 93.5 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 29.3 | 0.111 | 96.9 | 5.3 | 0.025 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 14.3 | 7.68 | -17.2 | 5.97 | 1.07 |